Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Camurus to present at Jefferies 2017 London Healthcare Conference

Lund, Sweden — 7 November 2017 — Camurus (Nasdaq Stockholm; CAMX) today announced that the Company will present at Jefferies 2017 London Healthcare Conference 16 November at 3:20 pm local time (GMT). Fredrik Tiberg, President and CEO, will update on the progress of the development pipeline, including the ongoing registration processes of CAM2038 weekly and monthly depots of buprenorphine developed for treatment of opioid dependence. A webcast of the presentation can be accessed live via Camurus website www.camurus.com. About CamurusCamurus is a Swedish research-based pharmaceutical

Tradedoubler interim report January – September 2017

Improved development THE THIRD QUARTER JULY – SEPTEMBER 2017 · Net sales amounted to SEK 258 M (304). Net sales adjusted for change related items were SEK 258 M (302), which was a decrease of 15%. · Gross profit adjusted for change related items was SEK 60 M (68), a decrease of 11% or 10% adjusted for changes in exchange rates. Gross margin adjusted for change related items was 23.4% (22.4). · Operating costs excluding depreciation and change related items were SEK 54 M (63), a decrease of 15%. · EBITDA amounted to SEK 10 M (4). Adjusted for change related items, EBITDA was

Finnair Traffic Performance in October 2017

Finnair Plc               Investor News             7 November 2017 at 09:00 am Revenue Passenger Kilometres increased by a fifth In October, Finnair's overall capacity measured in Available Seat Kilometres increased by 16.8 per cent year‐on‐year, and traffic measured in Revenue Passenger Kilometres grew by 19.9 per cent. The number of passengers carried in October was 1.06 million, corresponding to an increase of 13.2 per cent year-on-year. The passenger load factor increased by 2.1 percentage points to 82.0 per cent. The capacity in Finnair’s largest traffic area, Asia, increased

INTERIM REPORT, January–September 2017

Continued strong sales growth. Margin compression as raw material prices remain high.Third quarter of 2017      · Consolidated net sales increased by 23 percent to SEK 646 m (527), of which organic growth amounted to 5 percent. Acquisitions contributed by 18 percent and the currency translation effects were neutral · Net sales in Products & Solutions amounted to SEK 457 m (387) and Installation Services to SEK 218 m (167) · EBITDA before items affecting comparability increased by 5 percent to SEK 96 m (92) · Operating profit (EBIT) before items affecting comparability

Stora Enso delivers cloud-based intelligent packaging solutions enabled by Microsoft

STORA ENSO OYJ PRESS RELEASE 7 November 2017 at 09.00 EETStora Enso has joined forces with Microsoft to bring cloud-based intelligent packaging solutions to clients globally. Intelligent Packaging by Stora Enso utilizes Microsoft Azure, the leading cloud platform for business digitalization. The global and scalable cloud platform from Microsoft enables reliable and secure data collection and analytics for clients investing in innovative intelligent packaging solutions. Intelligent Packaging by Stora Enso integrates widely adopted RFID (Radio frequency identification) technology which

Nel ASA: Approved Prospectus and Commencement of the Subsequent Offering

(Oslo, 7 November 2017) Reference is made to the stock exchange release from Nel ASA (“Nel” or the “Company”) published on 27 September 2017 regarding the successful completion of a private placement of 88,000,000 new shares in the Company (the "Private Placement") and the subsequent repair offering of up to 10,000,000 new shares in the Company (the "Subsequent Offering"). The Norwegian Financial Supervisory Authority has approved the prospectus of the Company dated 6 November 2017 (the "Prospectus") related to the Private Placement, and the Subsequent Offering and listing of up to 10,

Cleantech Invest becomes Loudspring

Cleantech Invest has announced that it will release a strategy update later in November. We have today sent out an invitation to EGM that will on 29th of November decide on the proposed name change. Since the name change portion of the strategy update requires shareholder meeting approval and becomes public on EGM invitation, we will hereby be formally announcing that part of our strategy update separately.  Cleantech Invest is rebranding its name to Loudspring. The name “Loudspring” takes inspiration from Rachel Carson’s famous book The Silent Spring. In her book Carson focused on the

Notice to the Extraordinary General Meeting of Cleantech Invest Plc.

Notice is given to the shareholders of Cleantech Invest Plc. to the Extraordinary General Meeting to be held on Wednesday, 29 November 2017 at 17.00 p.m. (EET) at G Livelab, address Yrjönkatu 3, 00120 Helsinki, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at 16.30 p.m. (EET). A. Matters on the agenda of the General Meeting At the General Meeting, the following matters will be considered: 1. Opening of the meeting 2. Calling the meeting to order 3. Election of persons to scrutinize the minutes and to

Interim report January - September 2017

1 July - 30 September 2017● Revenue declined 1 per cent to SEK 1,414 M (1,432). Adjusted for currency effects and calculated on the    comparable number of workdays, revenue remained unchanged. Sales in comparable units declined 1 per cent, in local currency.● EBITA improved to SEK 157 M (154) and the EBITA margin was 11 per cent (11).● EBIT increased to SEK 127 M (125) and the EBIT margin was 9 per cent (9). EBIT was positively impacted by items affecting comparability of SEK 7 M (neg: 18).● The gross margin was 54.4 per cent (54.5). ● Earnings per share, before and after dilution,

Interim report January - September 2017

July – September 2017 · Consolidated revenue for the period was SEK 268.3 M (126.5), an increase of 112 per cent compared to 2016. · EBIT for the period was SEK 32.6 M (13.1), an increase of 149 per cent compared to 2016. · Net result for the period was SEK 27.9 M (10.9). · Earnings per share for the period, before dilution, was SEK 3.17 (1.24). · Cash flow before financing activities during the period was SEK 29.9 M (20.9). · For the free-to-play games the average Monthly Active Users (MAU) was 7.3 million, an increase of 93 per cent compared to the same period in 2016.

Tethys Oil AB: Third quarter and nine months report - 30 September 2017

Third quarter 2017 (second quarter 2017) ·        Production amounted to 12,354 bopd (12,477 bopd) ·        Revenue of MUSD 28.5 (MUSD 31.4) ·        EBITDA of MUSD 18.2 (MUSD 21.0) ·        Net result of MUSD 4.8 (MUSD 10.6) ·        Earnings per share amounted to USD 0.14 (USD 0.31) ·        Nine new wells completed on Blocks 3&4 ·        Two previously undrilled fault blocks on Farha South were drilled and found to be oil bearing ·        Exploration well Samah-1 is being drilled   MUSD (unless Third Second quarter 2017 Third quarter 2016

CLX Communications AB (publ): Interim report January - September 2017

January-September 2017 ·     Net sales increased by 87 percent to SEK 2,148.8 million (1,147.7). Organic growth was 8 percent.·     EBITDA amounted to SEK 187.2 million (52.5).·     EBITDA excluding items affecting comparability[1] (adjusted EBITDA) amounted to SEK 226.5 million (96.5).·     Operational foreign exchange differences affected operating profit for the period by SEK -5.0 million (8.2).·     EBIT amounted to SEK 93.8 million (48.8).·     Profit after tax for the period amounted to SEK 44.1 million (50.0).·     Basic and diluted earnings per share amounted to SEK

NRC Group ASA – Third quarter 2017 result report and presentation

Record results, solid order intake and strong market outlookToday, 7 November 2017, NRC Group has released its financial results for the third quarter of 2017. The company will present the results at 11.30 AM (CET) at Carnegie offices, Fjordallèen 16, Aker Brygge, Oslo. The presentation will be held by CEO Øivind Horpestad and CFO Dag Fladby. Below you will find a summary and highlights from the report. Key events: -       All time high quarterly revenue and EBITDA -       Record EBITDA margin driven by strong project execution -       Closed acquisitions of ALTi and SBB

Q3 2017 Interim report January−September

2017-11-07 Record Quarter and continued Strong Growth  Third quarter of 2017 – revenue and EBITDA record · Revenues totalled EUR 17.26 million (10.73), an increase of 61 percent year-on-year (YoY) and an increase of 15% compared with the previous quarter.  Search revenues were the highest so far with organic growth of 29%. Management estimates that 60% of revenues are generated from regulated markets. · EBITDA amounted to EUR 8.81 million (4.93) corresponding to an EBITDA margin of 51 percent (46). Adjusted EBITDA excluding non-recurring costs related to the change of listing

Cybermedia Center, Osaka University Adopts Asetek Liquid Cooling for New Computer System

November 7, 2017 – Asetek (ASETEK.OL) and Cybermedia Center, Osaka University, today announced that Cybermedia Center, Osaka University will incorporate Asetek RackCDU Direct-to-Chip ™ (D2C) liquid cooling for a new HPC (High Performance Computing) installation in Japan. This follows the announcement  of an undisclosed installation on September 7th, 2017. You can read more about the partnership at

Multiconsult ASA – Repurchase of own shares

On 6 November 2017, Multiconsult ASA ("Multiconsult") purchased 1 304 of its own shares at an average price of NOK 86.08 per share. The shares were purchased in accordance with the Company's share repurchase programme as announced on 22 September 2017. The shares were acquired on Oslo Børs.Following this transaction Multiconsult holds 111 571 of its own shares.   For further information, please contact: Investor relations:      Mirza Koristovic, Head of Investor Relations      Phone: +47 93 87 05 25      E-mail: ir@multiconsult.no Media:      Gaute Christensen, VP

New MenaQ7® Vitamin K2 Patents Granted

Successful examination period results in process patents in United States, Israel, and AustraliaOSLO, NORWAY and METUCHEN, NJ (7 November 2017) – NattoPharma ASA has announced it has successfully secured patents in Israel, the United States, and Australia for its nature-identical synthesis creating MenaQ7® PharmaPure Vitamin K2 as MK-7, enriching the company’s already robust patent portfolio.   • Israel: On July 31, 2017 patent #238199 “Process for preparation of MK-7 type of Vitamin K2” was granted. • United States: On August 28, 2017 Notice of Allowance for patent #14/435,260 “

Fortum has published offer document for Uniper shares, acceptance period has commenced

FORTUM CORPORATION STOCK EXCHANGE RELEASE 7 NOVEMBER 2017 8:00 EETFortum has today published the offer document for the voluntary public takeoveroffer (Offer) for the outstanding shares of Uniper following approval of theoffer document by the German Federal Financial Supervisory Authority (BaFin).The acceptance period has commenced today, 7 November 2017, and ends on 16January 2018.Pursuant to the Offer, Uniper shareholders who tender their shares will receivethe previously announced total value of EUR 22.00 per share in cash, whichincludes the value of an expected dividend

Alma’s image of red giant star gives a surprising glimpse of the Sun’s future

A Chalmers-led team of astronomers has for the first time observed details on the surface of an aging star with the same mass as the Sun. Alma:s images show that the star is a giant, its diameter twice the size of Earth’s orbit around the Sun, but also that the star’s atmosphere is affected by powerful, unexpected shock waves. The research is published  in Nature Astronomy on 30 October 2017. A team of astronomers led by Wouter Vlemmings, Chalmers University of Technology, have used the telescope Alma (Atacama Large Millimetre/

RESTAMAX PLC INTERIM REPORT FOR 1 JANUARY-30 SEPTEMBER 2017: Turnover and profitability continued to increase in January-September 2017

Restamax PlcINTERIM REPORT 7 November 2017 at 8:00 a.m.RESTAMAX PLC INTERIM REPORT FOR 1 JANUARY-30 SEPTEMBER 2017Turnover and profitability continued to increase in January-September 2017TURNOVER AND INCOMEGroup's result for July-September 2017Entire Group:The Group's turnover was MEUR 55.9 (MEUR 36.6), growth of 52.9 per cent. EBITDA was MEUR 7.5 (MEUR 6.4), growth of 16.8 per cent. Operating profit was MEUR 4.4 (MEUR 3.8), growth of 17.1 per cent.Restaurant business:The turnover of the restaurant business segment was MEUR 33.2 (MEUR 29.4), growth of 12.8 per cent.

FuchsRohr AluDrill: Drilling innovation made in Germany

· Lightweight, durable and field proven, FuchsRohrAluDrill pipe delivers extended drilling reach in challenging drilling environments · Field drilling operations show that the aluminum alloy pipe developed by OTTO FUCHS Drilling Solutions provides up to a 30% ROP improvement, compared to conventional steel pipes · See the next-generation AluDrill pipe at the OTTO FUCHS Drilling Solutions booth during ADIPEC in Abu Dhabi, UAE (Booth Number 8711 [German Pavilion], November 13-16, 2017).Meinerzhagen, Germany, November 6, 2017 – The innovative FuchsRohr AluDrill aluminum alloy pipe is a

Ossur Hf : Transactions in relation to share buyback program

Announcement from Össur hf. No. 80/2017Reykjavík, 6 November 2017 On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017.  The purpose of the share buyback program is to reduce the Company's share capital and adjust the capital structure by distributing capital to shareholders in line with the Company's Capital Structure and Dividend Policy. The program would end no later than 31 July 2018. The Company may purchase up to 5,000,000 shares under the program, corresponding to 1.1% of the current share capital. The total consideration for

Existing Rabeximod can be used in Cyxone's planned Phase 2b study in patients with rheumatoid arthritis

Cyxone has analysed the Rabeximod that was previously manufactured by OxyPharma for clinical trials at Syntagon AB. Results show that the existing substance, despite having been stored for several years, can be used in Cyxone's upcoming Phase 2b study in patients with rheumatoid arthritis.Consequently, Cyxone does not believe that it is necessary to produce new batches of Rabeximod. This represents a considerable saving for the company and facilitates the start of the clinical programme. November 1, 2017 ContactCyxone AB (publ)Kjell G. Stenberg, CEOTel: +46 (0)723 816168Email:

There are no items matching the current filter
There are no more items matching the current filter
Back to top